Avalon GloboCare (AVCO) Peer Comparison

$3.78

$-0.54 (-12.40%)

As on 11-Jan-2023 09:30EDT

Market cap

$52 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

256.1

Div. Yield

0 %

Edit

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	52	17,326	13,400	12,305	12,277
Revenue ($ Mln)	1	2,782	2,436	670	1,664
Net Profit ($ Mln)	-11.85	491.50	860.62	-319.95	413.60
Net Margin (%)	-955.40	17.67	35.33	-47.79	24.86
RoE (%)	-404.52	110.09	42.98	-71.14	430.03
Price to Earnings	--	36.49	17.01	--	31.17
Price-To-Book	256.07	39.43	7.27	26.44	83.92

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	1.24	1,142.38	1,434.97	138.29	443.31
Cost of Revenue	0.91	814.22	52.87	--	81.41
Gross Profit	0.41	328.16	1,382.10	138.29	361.90
Operating Expenses	7.80	129.54	1,095.43	287.32	86.00
Operating Profit (EBIT)	-8.82	198.62	286.67	-149.04	275.90
Other Income	0.00	3.34	-0.18	2.07	-19.86
Profit before Tax	-11.85	201.85	294.15	-140.85	248.52
Provision for Tax	0.00	20.00	63.09	0.00	-154.19
Profit after Tax (Net Income)	-11.85	181.85	231.06	-140.85	402.71
Minority Interest	0.00	--	--	--	--
Consolidated Profit	-6.43	181.85	231.06	-140.85	402.71

Liabilities ($ Mln)

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	4.58	952.93	2,210.62	408.82	196.95
Minority Interest	0.00	--	--	--	--
Non-Current Liabilities	5.01	149.79	68.03	154.79	790.33
Current Liabilities	3.33	557.22	337.59	146.54	117.15
Total Liabilities	10.24	1,659.94	2,616.24	710.15	1,104.43

Assets ($ Mln)

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	8.46	969.02	781.49	325.55	178.14
Current Assets	4.45	690.91	1,834.75	384.60	926.29
Total Assets	10.24	1,659.94	2,616.24	710.15	1,104.43
Total Debt*	4.60	130.97	51.27	25.55	876.67
Net Current Assets	1.12	133.70	1,497.16	238.06	809.14

Cashflow ($ Mln)

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-5.02	263.33	400.80	171.31	299.44
Cash Flow from Investing Activities	-0.07	-31.36	-42.88	-141.68	-406.29
Cash from Financing Activities	5.17	-44.45	-14.80	11.31	77.87
Net Cash Inflow / Outflow	--	187.51	52.64	40.85	-28.98

Ratios

Profitability Ratios

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-127.75	18.14	11.03	-30.71	49.66
ROE (%)	-404.52	20.68	11.30	-32.36	231.44
ROA (%)	-76.02	11.92	9.72	-22.85	47.82
EBIT Margin (%)	-673.49	--	--	--	--
Net Margin (%)	-955.40	15.87	16.10	-100.35	95.10
Cash Profit Margin (%)	0.00	--	--	--	--

Growth Ratios

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-17.95	0.23	0.45	0.57	0.66
EBIT Growth (%)	-27.02	--	--	--	--
Net Profit Growth (%)	-75.27	25.08	106.71	-66.58	211.97
EPS Growth (%)	--	0.25	1.04	-0.64	2.14
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	--	45.17	25.57	-46.33	14.40
Price / Book Value	--	8.62	2.67	15.96	29.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.60	35.34	14.96	-46.64	21.28
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	1.00	0.14	0.02	0.06	4.45
Short term debt to equity ratio	0.01	0.17	0.00	0.01	0.45
Current Ratio	1.34	1.24	5.43	2.62	7.91
Quick Ratio	1.34	--	5.35	2.59	7.45
Interest Coverage	-2.39	1,923.40	--	-23.01	36.66

Operating Efficiency Ratios

	Avalon GloboCare (AVCO)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	9.86	16.32	19.70	7.42	20.52
Asset Turnover	0.08	0.75	0.60	0.22	0.53
Receivable days	13.47	55.54	56.45	14.66	77.74
Inventory Days	--	0.00	167.40	--	257.19
Payable days	16.31	11.71	165.41	--	7.78
Cash Conversion Cycle	--	48.64	58.44	--	327.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly